Antitumor activity of emodin against pancreatic cancer depends on its dual role: Promotion of apoptosis and suppression of angiogenesis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Lin, Sheng Zhang ^a,c   Wei, Wei Tian ^b   Chen, Hui ^c   Chen, Kang Jie ^a   Tong, Hong Fei ^c   Wang, Zhao Hong ^c   Ni, Zhong Lin ^c   Liu, Hai Bin ^c   Guo, Hong Chun ^c   Liu, Dian Lei ^c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EMODIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; EMODIN; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; PANCREATIC NEOPLASMS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864426653     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042146     Document Type: Article

References (27)

1. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, et al. ((2005)) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:: 3509--3516.
2. Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, et al. ((2006)) Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24:: 4441--4447.
3. Gately S, Kerbel R, ((2003)) Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37:: 179--192.
4. North S, Moenner M, Bikfalvi A, ((2005)) Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 218:: 1--14.
5. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, et al. ((2007)) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:: 3853--3861.
6. Liu A, Chen H, Tong H, Ye S, Qiu M, et al. ((2011)) Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-kappaB. Mol Med Report 4:: 221--227.
7. Wang ZH, Chen H, Guo HC, Tong HF, Liu JX, et al. ((2011)) Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Int J Oncol 39:: 1123--1131.
8. Chen H, Wei W, Guo Y, Liu A, Tong H, et al. ((2011)) Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep 25:: 1253--1261.
9. Kaneshiro T, Morioka T, Inamine M, Kinjo T, Arakaki J, et al. ((2006)) Anthraquinone derivative emodin inhibits tumor-associated angiogenesis through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol 553:: 46--53.
10. Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, et al. ((2006)) Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 118:: 2711--2720.
11. Lu Y, Zhang J, Qian J, ((2008)) The effect of emodin on VEGF receptors in human colon cancer cells. Cancer Biother Radiopharm 23:: 222--228.
12. Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, et al. ((2010)) Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 22:: 1350--1362.
13. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, et al. ((2005)) Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65:: 9064--9072.
14. Crawford AD, Liekens S, Kamuhabwa AR, Maes J, Munck S, et al. ((2011)) Zebrafish bioassay-guided natural product discovery: isolation of angiogenesis inhibitors from East African medicinal plants. PLoS ONE 6:: e14694.
15. Carbone C, Melisi D, ((2012)) NF-kappaB as a target for pancreatic cancer therapy. Expert Opin Ther Targets 16 (Suppl 2): S1--10.
16. Meng F, Henson R, Patel T, ((2007)) Chemotherapeutic stress selectively activates NF-kappa B-dependent AKT and VEGF expression in liver cancer-derived endothelial cells. Am J Physiol Cell Physiol 293:: C749--760.
17. Babykutty S, Kumar MA, Nair MS, et al. ((2011)) Nimbolide retards tumor cell migration, invasion, and angiogenesis by downregulating MMP-2/9 expression via inhibiting ERK1/2 and reducing DNA-binding activity of NF-kappaB in colon cancer cells. Mol Carcinogen 51:: 475--490.
18. Ye Y, Martinez JD, Perez-Polo RJ, Lin Y, Uretsky BF, et al. ((2008)) The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 295:: H343--351.
19. Liu H, Chen A, Guo F, Yuan L, ((2010)) A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 295:: 27--37.
20. Liu A, Chen H, Wei W, Ye S, Liao W, et al. ((2011)) Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer. Oncol Rep 26:: 81--89.
21. Ferrara N, Alitalo K, ((1999)) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:: 1359--1364.
22. Yin JH, Shi WD, Zhu XY, Chen Z, Liu LM, ((2011)) Qingyihuaji Formula Inhibits Progress of Liver Metastases From Advanced Pancreatic Cancer Xenograft by Targeting to Decrease Expression of Cyr61 and VEGF. Integr Cancer Ther 11:: 37--47.
23. Aggarwal BB, ((2004)) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:: 203--208.
24. Lu HF, Lai KC, Hsu SC, Lin HJ, Kuo CL, et al. ((2009)) Involvement of matrix metalloproteinases on the inhibition of cells invasion and migration by emodin in human neuroblastoma SH-SY5Y cells. Neurochem Res 34:: 1575--1583.
25. Chen TG, Chen JZ, Wang XX, ((2006)) Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif 39:: 117--125.
26. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC, ((1997)) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100:: 3131--3139.
27. Bahlmann FH, DeGroot K, Duckert T, Niemczyk E, Bahlmann E, et al. ((2003)) Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64:: 1648--1652.